Page last updated: 2024-10-15

PF-07304814

Description

lufotrelvir: lufotrelvir is the phosphate prodrug of PF-00835231 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

PF-07304814 : An indolecarboxamide resulting from the formal condensation of the carboxy group of 4-methoxy-1H-indole-2-carboxylic acid with the primary amino group of N-[(2S)-3-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]-4-(phosphonooxy)butan-2-yl]-L-leucinamide. It is the phosphate prodrug of PF-00835231, an anticoronaviral agent. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID154699467
CHEMBL ID4802214
CHEBI ID173073
SCHEMBL ID24208597

Synonyms (28)

Synonym
(3s)-3-({n-[(4-methoxy-1h-indol-2-yl)carbonyl]-l-leucyl}amino)-2-oxo-4-[(3s)-2-oxopyrrolidin-3-yl]butyl dihydrogen phosphate
pf 07304814
pf07304814
(3s)-3-{[(2s)-2-{[(4-methoxy-1h-indol-2-yl)carbonyl]amino}-4-methylpentanoyl]amino}-2-oxo-4-[(3s)-2-oxopyrrolidin-3-yl]butyl dihydrogen phosphate
CHEBI:173073
pf-07304814
gtpl11249
[(3s)-3-[(2s)-2-[(4-methoxy-1h-indol-2-yl)formamido]-4-methylpentanamido]-2-oxo-4-[(3s)-2-oxopyrrolidin-3-yl]butoxy]phosphonic acid
lufotrelvir
CHEMBL4802214
EX-A4702
lufotrelvir [usan]
4-methoxy-n-((2s)-4-methyl-1-oxo-1-(((2s)-3-oxo-1-((3s)-2-oxopyrrolidin-3-yl)-4-(phosphonooxy)butan-2-yl)amino)pentan-2-yl)-1h-indole-2-carboxamide
xj51yob1sc ,
unii-xj51yob1sc
1h-indole-2-carboxamide, 4-methoxy-n-((1s)-3-methyl-1-((((1s)-2-oxo-1-(((3s)-2-oxo-3-pyrrolidinyl)methyl)-3-(phosphonooxy)propyl)amino)carbonyl)butyl)-
2468015-78-1
who 12095
bdbm510049
''wo2021205298, compound 49
lufotrelvir [who-dd]
lufotrelvir [inn]
CS-0144500
DTXSID501337108
HY-138078
[(3~{s})-3-[[(2~{s})-2-[(4-methoxy-1~{h}-indol-2-yl)carbonylamino]-4-methyl-pentanoyl]amino]-2-oxidanylidene-4-[(3~{r})-2-oxidanylidene-3,4-dihydropyrrol-3-yl]butyl] dihydrogen phosphate
SCHEMBL24208597
AKOS040759875
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
prodrugA compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug.
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitorAn EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of SARS coronavirus main proteinase (EC 3.4.22.69).
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
indolecarboxamide
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
pyrrolidin-2-onesA pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring.
L-leucine derivativeA proteinogenic amino acid derivative resulting from reaction of L-leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-leucine by a heteroatom.
phosphate monoesterAn organic phosphate that is phosphoric acid in which one of the hydrogens is replaced by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1821845Inhibition of SARS-CoV-2 3CL protease2022European journal of medicinal chemistry, Feb-05, Volume: 229Design, synthesis and in vitro evaluation of novel SARS-CoV-2 3CL
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's8 (100.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (25.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]